Free Trial
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

Chemomab Therapeutics logo
$1.02 -0.05 (-4.21%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$1.03 +0.01 (+0.98%)
As of 08/1/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Chemomab Therapeutics Stock (NASDAQ:CMMB)

Key Stats

Today's Range
$1.02
$1.07
50-Day Range
$1.03
$1.40
52-Week Range
$0.87
$2.55
Volume
106,220 shs
Average Volume
129,046 shs
Market Capitalization
$19.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Chemomab Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

CMMB MarketRank™: 

Chemomab Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 405th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Chemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Chemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Chemomab Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chemomab Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chemomab Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Chemomab Therapeutics has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Chemomab Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.03% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently increased by 9.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Chemomab Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Chemomab Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.03% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently increased by 9.30%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Chemomab Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Chemomab Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for CMMB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Chemomab Therapeutics' insider trading history.
Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMMB Stock News Headlines

Microsoft's Next Big Bet?
Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-free energy. Bill Gates calls it “abundant” and is backing four separate startups in the space. While most of these plays are off-limits to everyday investors, a little-known backdoor could give you access to one tiny company leading the charge—and it’s publicly traded.
See More Headlines

CMMB Stock Analysis - Frequently Asked Questions

Chemomab Therapeutics' stock was trading at $1.81 on January 1st, 2025. Since then, CMMB shares have decreased by 43.4% and is now trading at $1.0250.

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06.

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE).

Company Calendar

Last Earnings
5/15/2025
Today
8/02/2025
Next Earnings (Estimated)
8/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CMMB
CIK
1534248
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$7.00
Potential Upside/Downside
+729.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-106.70%
Return on Assets
-82.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.33
Quick Ratio
5.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.72 per share
Price / Book
1.42

Miscellaneous

Outstanding Shares
18,860,000
Free Float
16,611,000
Market Cap
$19.33 million
Optionable
Not Optionable
Beta
0.52
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CMMB) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners